NorthWest Biotherapeutics Inc (NWBO)

[GermanCol]

you can not ignore NWBO's failure to disclose the data. That is such a huge issue that I fall to see how anybody can ignore it.

Again, this issue you keep repeating is absurd and misleading. The company hasn't disclosed that information not for any hidden negative reasons as you are implying. They haven't done it because it doesn't make any sense to compare:232 randomized patients to:

1. The 99 original placebo arm, because 64 of them received DCVax
2. The 35 (99-64) non crossover patients, because they lost all of the randomization. What was randomized was the whole 99 original placebo arm and the ones that remained in the non-crossover group were the ones that didn't crossover. These 35 patients are not the result of any randomization.

In any case you would be comparing apples to oranges.

Having said that, I have to say that I agree with what flipper have been saying:

So additionally, I’d point out you have already claimed multiple times the original main OS endpoint failed, that the original experimental arm is worse than control, and they will never show it. You don’t know any of this is true. They are still conducting follow up. Those results have not been released. You don’t understand impacts of censoring removal.

I think that in the case they found those LTFU, that would benefit the arms comparison in DCVax's favor for the previous OS endpoint because of the following reasons:

1. The effect of not having censors and instead having the actual information for sicker patients would affect negatively an arm in the trial as flipper explained in some of his posts and I expained in the post I'm linking below.

2. All of the censors in the 2018 JTM interim results publication for the first 16 months from randomization (19 months from surgery) were left censors (LTFUs) and also all of them were part of the original control arm (99 patients arm). None of them were part of the treatment arm (232 patients arm). And these are the reasons:

- In JAMA article with final results there were no censors for the first two years from randomization for the treatment arm (232 patients arm), while in the 2018 JTM interim results publication there were 13 censors for the first 19 months from surgery (16 from randomization) that were necessarily LTFU because of the time from enrollment of the last patient.

- Those LTFU patients were not just taken out of the treatment arm because it continued having 232 patients as before.

All of these details are explained in post 479394 in the following link:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168995681